<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533672</url>
  </required_header>
  <id_info>
    <org_study_id>SBCT</org_study_id>
    <nct_id>NCT04533672</nct_id>
  </id_info>
  <brief_title>Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making</brief_title>
  <acronym>SBCT</acronym>
  <official_title>Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The therapeutic approach to bladder cancer is strongly dependent on tumor stage and grade.&#xD;
      Patients with non-muscle-invasive tumors (NMIBC) are usually treated with surgical resection&#xD;
      of the tumor alone, whereas patients with muscle-invasive tumors (MIBC) ideally undergo&#xD;
      neoadjuvant chemotherapy (NCT) and subsequent cystectomy. Magnetic Resonance Imaging (MRI) is&#xD;
      emerging as a new staging modality, given its non-invasiveness and excellent soft tissue&#xD;
      contrast. However, more advanced multiparametric MRI techniques are yet to be comprehensively&#xD;
      investigated in patients with bladder cancer. Recently, genetic characteristics of bladder&#xD;
      tumors have been identified that show significant impact on response rates to neoadjuvant&#xD;
      treatment. The combination of new multiparametric MRI (mpMRI) techniques and genetic analyses&#xD;
      of the tumor might allow for a better assessment of the expected clinical course of the&#xD;
      disease and support more personalized treatment approaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle-invasiveness</measure>
    <time_frame>through study completion, an average of 4 years</time_frame>
    <description>Presence of tumor infiltration into the muscular bladder wall, as per pathology report (infiltration: yes/no)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Single study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI Sequences</intervention_name>
    <description>New multiparametric MRI techniques</description>
    <arm_group_label>Single study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed or suspected primary bladder cancer and a circumscribed&#xD;
             tumor/focal thickening of the bladder wall on initial imaging (ultrasound, CT) or&#xD;
             cystoscopy with an approx. size of ≥ 1.5 cm/for which at least 2-3 TUR-B resection&#xD;
             loops are necessary&#xD;
&#xD;
          -  Informed consent as documented by signature (Informed Consent Form)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior TUR-B or other bladder treatment, prior treated bladder cancers, prior pelvic&#xD;
             irradiation&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding. Female participants who are surgically&#xD;
             sterilized / hysterectomized or post-menopausal for longer than 2 years are not&#xD;
             considered as being of childbearing potential.&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant&#xD;
&#xD;
          -  Previous enrolment into the current study&#xD;
&#xD;
          -  Patients with non-MRI compatible metallic or electronic implants, devices or metallic&#xD;
             foreign bodies (cardiac pacemaker, shrapnel, cochlea implants, neurostimulator, or&#xD;
             other non-MRI compatible implants).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Hötker, MD</last_name>
    <phone>+41 44 255 29 20</phone>
    <email>andreas.hoetker@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hötker, MD</last_name>
      <email>andreas.hoetker@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Hötker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

